General Electric (NYSE: GE) reported third-quarter 2020 financial results before the opening bell on Wednesday. The industrial giant reported a 17% decline in Q3 revenues to $19.4 billion, which fell short of the Wall Street consensus. Meanwhile, the company surprised the street with a profit of $0.06 per share, even as investors were anticipating a loss.
GE shares gained 3.5% immediately following the announcement. The stock has fallen 40% since the beginning of this year.
CEO H. Lawrence Culp, Jr. said in a statement, “We are improving our profit and cash performance with organic margin expansion in every segment except Aviation, though orders more broadly remain under pressure.”
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated